MX2009003909A - Métodos para dosificar un compuesto 1,2,4, - oxadiazol oralmente activo para el tratamiento de supresión de la mutación finalizadora. - Google Patents
Métodos para dosificar un compuesto 1,2,4, - oxadiazol oralmente activo para el tratamiento de supresión de la mutación finalizadora.Info
- Publication number
- MX2009003909A MX2009003909A MX2009003909A MX2009003909A MX2009003909A MX 2009003909 A MX2009003909 A MX 2009003909A MX 2009003909 A MX2009003909 A MX 2009003909A MX 2009003909 A MX2009003909 A MX 2009003909A MX 2009003909 A MX2009003909 A MX 2009003909A
- Authority
- MX
- Mexico
- Prior art keywords
- oxadiazole
- dosing
- methods
- nonsense mutation
- orally active
- Prior art date
Links
- 108020004485 Nonsense Codon Proteins 0.000 title abstract 3
- 230000037434 nonsense mutation Effects 0.000 title abstract 3
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000001629 suppression Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- -1 1,2,4-oxadiazole benzoic acid compound Chemical class 0.000 abstract 1
- OOUGLTULBSNHNF-UHFFFAOYSA-N 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(ON=2)C=2C(=CC=CC=2)F)=C1 OOUGLTULBSNHNF-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Abstract
La presente invención se refiere a las dosis específicas de y a los esquemas de dosificación para el uso de un compuesto ácido 1,2,4-oxadiazol benzóico para el tratamiento o prevención de enfermedades asociadas con mutaciones finalizadoras o sin sentido. En particular, la invención se refiere a las dosis específicas y a los esquemas de dosificación para el uso de ácido 3-[5-(2-fluorofenil)-[1,2,4]-oxadiazol-3-il]-benzóico en mamíferos que tienen enfermedades asociadas con mutaciones finalizadoras.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85145006P | 2006-10-12 | 2006-10-12 | |
| PCT/US2007/021921 WO2008045566A1 (en) | 2006-10-12 | 2007-10-11 | Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009003909A true MX2009003909A (es) | 2009-05-25 |
Family
ID=39102963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009003909A MX2009003909A (es) | 2006-10-12 | 2007-10-11 | Métodos para dosificar un compuesto 1,2,4, - oxadiazol oralmente activo para el tratamiento de supresión de la mutación finalizadora. |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US9226919B2 (es) |
| EP (2) | EP2460520B1 (es) |
| JP (4) | JP2010506840A (es) |
| KR (4) | KR20090074231A (es) |
| CN (2) | CN101553226B (es) |
| AU (1) | AU2007308067B2 (es) |
| BR (2) | BRPI0719276A2 (es) |
| CA (1) | CA2675518C (es) |
| CL (1) | CL2007002923A1 (es) |
| DK (1) | DK2073805T3 (es) |
| ES (1) | ES2538359T3 (es) |
| HR (1) | HRP20150590T1 (es) |
| IL (2) | IL198147A (es) |
| MX (1) | MX2009003909A (es) |
| NO (1) | NO342061B1 (es) |
| PE (4) | PE20212245A1 (es) |
| PL (1) | PL2073805T3 (es) |
| PT (1) | PT2073805E (es) |
| RS (1) | RS54025B1 (es) |
| RU (1) | RU2462247C2 (es) |
| SI (1) | SI2073805T1 (es) |
| TW (1) | TWI405570B (es) |
| WO (1) | WO2008045566A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3549936T3 (da) | 2003-04-11 | 2021-07-12 | Ptc Therapeutics Inc | 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense-undertrykkelse og behandlingen af sygdom |
| RU2462246C2 (ru) * | 2006-03-30 | 2012-09-27 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы получения функционального белка из днк, имеющей нонсенс-мутацию, и лечения нарушений, ассоциированных с ней |
| ES2538359T3 (es) | 2006-10-12 | 2015-06-19 | Ptc Therapeutics, Inc. | Métodos para administrar un 1,2,4-oxadiazol activo por vía oral para terapia de supresión de mutación sin sentido |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| CA3174516A1 (en) * | 2014-03-06 | 2015-09-11 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
| IL302218B2 (en) | 2014-08-28 | 2024-10-01 | Eisai R&D Man Co Ltd | Methods for manufacturing high-purity lenvatinib and its derivatives |
| JP6792546B2 (ja) * | 2015-02-25 | 2020-11-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体の苦味抑制方法 |
| EP3311841B1 (en) | 2015-06-16 | 2021-07-28 | PRISM BioLab Co., Ltd. | Anticancer agent |
| CN108135894B (zh) | 2015-08-20 | 2021-02-19 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| TW201729807A (zh) | 2015-10-30 | 2017-09-01 | Ｐｔｃ治療公司 | 用於治療癲癇的方法 |
| RU2750539C2 (ru) | 2017-02-08 | 2021-06-29 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Фармацевтическая композиция для лечения опухоли |
| AU2018269996A1 (en) | 2017-05-16 | 2019-11-21 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| MX2020003701A (es) | 2017-10-19 | 2020-07-22 | Cipla Usa Inc | Sintesis de analogos de aminoglucosidos antibacterianos. |
| EP3713934B1 (en) | 2017-11-23 | 2022-04-13 | Universita' degli Studi di Palermo | Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations |
| MX2021012428A (es) | 2019-04-10 | 2022-01-19 | Ptc Therapeutics Inc | Metodo para el tratamiento de distrofia muscular de duchenne mediada por mutacion sin sentido en pacientes pediatricos. |
| KR102378381B1 (ko) * | 2021-08-23 | 2022-03-24 | 라이보텍(주) | 넌센스-매개 mRNA 분해를 억제하기 위한 화합물 |
| EP4295850A4 (en) * | 2021-02-16 | 2025-03-05 | Ribotech Co., Ltd. | COMPOUND FOR INHIBITING NONSENSE-MEDIATED mRNA DEGRADATION |
| US20240358857A1 (en) * | 2021-05-11 | 2024-10-31 | Regenxbio Inc. | Treatment of duchenne muscular dystrophy and combinations thereof |
| KR102665711B1 (ko) * | 2021-12-21 | 2024-05-14 | 재단법인 아산사회복지재단 | Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물 |
| CN119638642A (zh) * | 2023-12-12 | 2025-03-18 | 暨南大学 | 双环类化合物及其药物组合物和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| CN1638776A (zh) * | 2001-06-08 | 2005-07-13 | 西托维亚公司 | 取代的3－芳基－5－芳基－[1,2,4]－噁二唑和类似物 |
| MY151199A (en) * | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
| TW200812986A (en) * | 2002-08-09 | 2008-03-16 | Nps Pharma Inc | New compounds |
| GB0303503D0 (en) * | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| DK3549936T3 (da) * | 2003-04-11 | 2021-07-12 | Ptc Therapeutics Inc | 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense-undertrykkelse og behandlingen af sygdom |
| US20050075375A1 (en) * | 2003-05-14 | 2005-04-07 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis C virus |
| CA2550866A1 (en) * | 2003-12-23 | 2005-07-14 | Alza Corporation | Methods and dosage forms for increasing solubility of drug compositions for controlled delivery |
| ES2683359T3 (es) * | 2005-04-08 | 2018-09-26 | Ptc Therapeutics, Inc. | Composiciones que comprenden un 1,2,4-oxadiazol y usos de las mismas para tratar enfermedades asociadas con un codón de parada prematura |
| US20070010553A1 (en) * | 2005-07-01 | 2007-01-11 | Astrazeneca Ab | New use |
| MX2009002439A (es) | 2006-09-08 | 2009-03-27 | Ptc Therapeutics Inc | Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos. |
| PL2076501T3 (pl) | 2006-09-25 | 2016-06-30 | Ptc Therapeutics Inc | Postacie krystaliczne kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]-benzoesowego |
| ES2538359T3 (es) | 2006-10-12 | 2015-06-19 | Ptc Therapeutics, Inc. | Métodos para administrar un 1,2,4-oxadiazol activo por vía oral para terapia de supresión de mutación sin sentido |
-
2007
- 2007-10-11 ES ES07852738.9T patent/ES2538359T3/es active Active
- 2007-10-11 SI SI200731657T patent/SI2073805T1/sl unknown
- 2007-10-11 RS RS20150384A patent/RS54025B1/sr unknown
- 2007-10-11 KR KR1020097009602A patent/KR20090074231A/ko not_active Ceased
- 2007-10-11 RU RU2009117590/15A patent/RU2462247C2/ru active
- 2007-10-11 PL PL07852738T patent/PL2073805T3/pl unknown
- 2007-10-11 US US11/974,068 patent/US9226919B2/en active Active
- 2007-10-11 JP JP2009532453A patent/JP2010506840A/ja active Pending
- 2007-10-11 BR BRPI0719276-2A2A patent/BRPI0719276A2/pt not_active Application Discontinuation
- 2007-10-11 WO PCT/US2007/021921 patent/WO2008045566A1/en not_active Ceased
- 2007-10-11 BR BR122019020961A patent/BR122019020961B8/pt active IP Right Grant
- 2007-10-11 KR KR1020167030361A patent/KR20160128468A/ko not_active Ceased
- 2007-10-11 MX MX2009003909A patent/MX2009003909A/es active IP Right Grant
- 2007-10-11 EP EP12152282.5A patent/EP2460520B1/en active Active
- 2007-10-11 AU AU2007308067A patent/AU2007308067B2/en not_active Ceased
- 2007-10-11 CN CN200780045655.9A patent/CN101553226B/zh not_active Expired - Fee Related
- 2007-10-11 CL CL200702923A patent/CL2007002923A1/es unknown
- 2007-10-11 CA CA2675518A patent/CA2675518C/en active Active
- 2007-10-11 PT PT78527389T patent/PT2073805E/pt unknown
- 2007-10-11 HR HRP20150590TT patent/HRP20150590T1/hr unknown
- 2007-10-11 DK DK07852738.9T patent/DK2073805T3/da active
- 2007-10-11 KR KR1020157013882A patent/KR101758341B1/ko not_active Expired - Fee Related
- 2007-10-11 EP EP07852738.9A patent/EP2073805B1/en active Active
- 2007-10-11 CN CN201310098430.7A patent/CN103211766B/zh not_active Expired - Fee Related
- 2007-10-11 KR KR1020177023924A patent/KR20170100072A/ko not_active Ceased
- 2007-10-12 TW TW096138340A patent/TWI405570B/zh not_active IP Right Cessation
- 2007-10-12 PE PE2020002230A patent/PE20212245A1/es unknown
- 2007-10-12 PE PE2011001559A patent/PE20120670A1/es not_active Application Discontinuation
- 2007-10-12 PE PE2007001386A patent/PE20080982A1/es not_active Application Discontinuation
- 2007-10-12 PE PE2016000659A patent/PE20160947A1/es unknown
-
2009
- 2009-04-16 IL IL198147A patent/IL198147A/en active IP Right Grant
- 2009-05-08 NO NO20091826A patent/NO342061B1/no unknown
-
2013
- 2013-10-25 JP JP2013222531A patent/JP6129713B2/ja not_active Expired - Fee Related
-
2014
- 2014-12-30 IL IL236519A patent/IL236519A/en active IP Right Grant
-
2015
- 2015-10-08 JP JP2015200029A patent/JP6333227B2/ja not_active Expired - Fee Related
- 2015-12-17 US US14/972,269 patent/US9522137B2/en not_active Expired - Fee Related
-
2016
- 2016-11-08 US US15/345,748 patent/US9737513B2/en not_active Expired - Fee Related
- 2016-12-08 JP JP2016238230A patent/JP2017081946A/ja active Pending
-
2017
- 2017-07-07 US US15/643,724 patent/US9877952B2/en active Active
-
2018
- 2018-01-19 US US15/875,296 patent/US10172836B2/en active Active
- 2018-12-04 US US16/208,663 patent/US10849885B2/en not_active Expired - Fee Related
-
2020
- 2020-10-23 US US17/078,092 patent/US20210038572A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009003909A (es) | Métodos para dosificar un compuesto 1,2,4, - oxadiazol oralmente activo para el tratamiento de supresión de la mutación finalizadora. | |
| UA99265C2 (ru) | Способ получения 1,2,4-оксадиазолбензойной кислоты и ее производных (варианты) | |
| NO20075682L (no) | Sammensetninger omfattende et oralt aktivt 1,2,4-oksadiazol for nonsense mutasjonsundertrykkelsesterapi | |
| Hashimoto et al. | Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders | |
| TW200637558A (en) | Solid, modified-release pharmaceutical dosage forms which can be administered orally | |
| CY1119001T1 (el) | Ενωσεις 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτων για ανευ νοηματος καταστολη και τη θεραπεια ασθενειας | |
| JP2016512558A5 (es) | ||
| NZ602125A (en) | Uses of dgat1 inhibitors | |
| NZ616806A (en) | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor | |
| AR062658A1 (es) | Terapias de combinacion para artritis reumatoide | |
| MX2010010334A (es) | Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida. | |
| WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
| MX2010007426A (es) | Composiciones farmaceuticas para tratar trastorno del higado graso. | |
| EP1666064A4 (en) | MEANS FOR THE TREATMENT OF DISEASES RELATED TO IMMUNOGLOBULIN GEN TRANSLATION | |
| BRPI0607003A2 (pt) | forma de dosagem com liberação sustentada e método para liberação sustentada de um composto de pirazina substituìda | |
| Mensink et al. | Novel antipsychotics in bipolar and schizoaffective mania | |
| WO2010054001A3 (en) | D-tagatose-based compositions and methods for preventing and treating atherosclerosis, metabolic syndrome, and symptoms thereof | |
| CY1116360T1 (el) | Μεθοδοι για δοσολογηση μιας εκ του στοματος χορηγουμενης δραστικης 1,2,4-οξαδιαζολης για θεραπεια καταστολης μη-νοηματικων μεταλλαξεων | |
| NZ585922A (en) | Use of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-benzoic acid in the treatment of prostate enlargement | |
| CA2434900A1 (en) | New use of iloperidone | |
| WO2009024820A3 (en) | Therapeutic treatment 014 | |
| Lattanzi | Hyperamylasaemia (first report) and hyperlipaseaemia: case report | |
| De Gusmao | Asthenia: case report | |
| AU2011328673A8 (en) | Compound for increasing kinase active and application thereof | |
| EA200970125A1 (ru) | Применение флумазенила в производстве лекарственного средства для лечения депрессивных расстройств |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration |